《关于公司股价异动的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近日，美好医疗发布关于公司股价异动的公告。公告称，公司股票在2026年1月5日、6日连续两个交易 日收盘价格涨幅偏离值累计达到40.32%，触发股票交易异常波动。公司经核查确认，前期披露信息无 误，未发现重大未公开信息，经营情况正常，内外部环境无重大变化，控股股东、实际控制人及董事在 异动期间无买卖公司股票行为。董事会确认无应披露未披露事项，不存在违反信息披露公平原则的情 形。公司指定信息披露媒体为《中国证券报》《证券时报》《证券日报》《上海证券报》及巨潮资讯 网。 最新公告列表 截至2026年1月6日收盘，美好医疗（301363）报收于34.63元，较前一交易日上涨19.99%，最新总市值 为197亿元。该股当日开盘34.63元，最高34.63元，最低34.63元，成交额达1.36亿元，换手率为1.05%。 ...

（编辑 丛可心） 证券日报网讯 1月6日，美好医疗发布公告称，公司股票2026年1月5日、6日连续两个交易日收盘价格涨 幅偏离值累计达40.32%（超过30%），触发异常波动。公司核查后表示，前期披露信息无需更正，经营 正常，未发现未公开重大信息，控股股东及董监高在波动期间未买卖股票，不存在应披露未披露事项。 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：财富投资网 摘要：脑机接口概念股持续上演涨停潮：连续两天涨停的个股家数高达20只。因此，投资参股脑机接口 企业的相关上市公司值得关注。 周二A股市场几大指数全面强势上扬，尤其是连续第13个交易日收阳线的上证指数再度创下十年来的新 高，市场整体的成交量在元旦节后呈现明显放大的趋势，表明A股市场经过了前一阶段的整固和蓄势， 在开年后已经进入了新的一轮健康稳步上升的周期中！从市场热点来看，周一已经进入全面大爆发阶段 的脑机接口概念在周二的市场人气热度继续发酵，创新医疗（002173）、岩山科技（002195）、三博脑 科（301293）、美好医疗（301363）、南京熊猫（600775）这几只脑机接口概念股已经连续两个交易日 股价封"一"字涨停板，其它在周二封"一"字板涨停的脑机接口概念股还包括普力特（002324）、国际医 学（000516）、塞力医疗（603716）、倍益康（920199）和嘉事堂（002462），另外还有翔宇医疗 （688626）、爱朋医疗（300753）、熵基科技（301330）、伟思医疗（688580）、谱尼测 ...

Core Viewpoint - The medical sector is experiencing significant activity, particularly driven by advancements in brain-computer interface (BCI) technology, which is attracting investor interest and leading to substantial market movements in related stocks and ETFs [3][10][11]. Market Performance - On January 6, 2026, the largest medical ETF (512170) saw a recovery, closing up 1.12% with a total trading volume of 1.017 billion yuan, marking two consecutive days of trading over 1 billion yuan [1][8]. - The ETF's index, which includes 12 related concept stocks, has a combined weight exceeding 36%, indicating strong sector representation [11][13]. Stock Highlights - Brain-computer interface stocks, such as Sanbo Brain Science and Meihua Medical, reached their daily limit up, while stocks like Yingke Medical and Hejing Biological experienced declines [1][8]. - The BCI sector is expected to see increased valuations for related listed companies, potentially boosting market financing and capital development [3][10]. Technological Advancements - A recent breakthrough in BCI technology was reported by Fudan University Huashan Hospital, which successfully completed the first clinical trial of a fully implanted, wireless, and functional BCI product [3][10]. - The BCI technology is positioned as a key area of investment, with potential applications in disease treatment and long-term enhancements for humans, opening up a market space worth trillions [10][11]. Investment Insights - According to CITIC Construction Investment, the current valuation of the medical index is 34.28 times, which is below the 70% threshold of the past decade, suggesting a favorable investment opportunity [4][11]. - The medical ETF (512170) is recognized as an efficient tool for accessing core medical assets, with a total size exceeding 26.4 billion yuan, making it the largest medical ETF in the market [6][13].

证券代码：301363 证券简称：美好医疗 公告编号：2026-001 深圳市美好创亿医疗科技股份有限公司 关于公司股价异动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）股票（证券代码： 301363，证券简称：美好医疗）2026年1月5日、6日连续两个交易日收盘价格涨幅偏 离值累计达到40.32%（超过30％），根据深圳证券交易所的有关规定，属于股票交 易异常波动的情形。 二、公司关注及核实情况说明 4、经核实，公司、控股股东和实际控制人不存在关于本公司的应披露而未披露 的重大事项，或处于筹划阶段的重大事项。 5、在公司本次股票异常波动期间，不存在公司控股股东、实际控制人及公司董 事买卖公司股票的情况。 三、是否存在应披露而未披露信息的说明 公司董事会确认，除在指定媒体已公开披露的信息外，公司目前没有任何根据 《深圳证券交易所创业板股票上市规则》等有关规定应予以披露而未披露的事项或 1 与该事项有关的筹划、商谈、意向、协议等；董事会也未获悉公司有根据《深圳证 券交 ...

Core Insights - The market experienced a strong performance with 120 stocks hitting the daily limit up, and a total of 43 stocks classified as consecutive limit-up stocks, indicating a bullish sentiment among investors [1] - The advancement rate of consecutive limit-up stocks reached 71.42%, excluding ST and delisted stocks, showcasing a significant increase in market enthusiasm [1] Group 1: Market Performance - Over 4,100 stocks rose in the market, with more than 100 stocks hitting the limit up for the second consecutive trading day [1] - The stock of Victory Energy, which resumed trading, achieved a limit up with a T-shaped pattern, marking its 13th consecutive limit-up [1] - Jia Mei Packaging, which underwent a shareholding change, also saw a limit up, achieving 12 limit-ups over 16 days [1] Group 2: Sector Performance - Resource stocks, particularly in non-ferrous metals and chemicals, showed strong performance, with Luoyang Molybdenum and Zijin Mining both rising over 6% to reach historical highs [1] - Hengli Petrochemical has increased over 20% since December, reaching a nearly four-year high [1] Group 3: Emerging Concepts - The brain-computer interface sector continued its strong momentum, with nearly 20 stocks achieving consecutive limit-ups, including Sanbo Brain Science, Meihao Medical, and Aipeng Medical [1] - The commercial aerospace concept remained active, with notable performances from large-cap stocks such as China Satellite Communications, which achieved 4 limit-ups in 6 days, and Goldwind Technology, which hit a limit up and reached a historical high [1]

沪指罕见13连阳 商业航天、脑机接口概念狂飙 1月6日，A股、港股延续"开门红"行情继续走高，沪指罕见13连阳刷新纪录。黄金白银续演超牛行情，白银大涨超3%，黄金站上4460美 元。 具体来看，A股三大指数高开高走，截至收盘，上证指数收涨1.5%，实现13连阳，创出史上最长连阳纪录，创逾10年新高。 全市场逾4100股上涨，其中有143只个股涨停，连续两日超百股涨停。沪深两市成交额2.83万亿元，创逾三个月新高。 板块方面，商业航天概念全天强势，十余只成分股涨停，鲁信创投（600783）8天6板，北斗星通（002151）、中国卫通（601698）6天4 板，金风科技（002202）走出7天3板。 分析：与AI竞赛夺关键资源趋势相关 有色金属板块表现活跃，洛阳钼业（603993）、紫金矿业（601899）等多股创历史新高，其中紫金矿业涨逾6%，总市值突破万亿元。 在牛市氛围下，登云股份（002715）（002715.SZ）开盘即遭遇跌停，总市值较前一交易日大幅缩水，为当前A股市场唯一非ST跌停股。消 息面上，登云股份1月5日晚间公告称，公司实际控制人杨涛被逮捕，其涉嫌罪名为非法吸收公众存款罪。 港股方面，截至1 ...

Market Overview - The Shanghai Composite Index experienced a rare 13 consecutive days of gains, breaking the previous high from November 14, 2025, and reaching a new high since July 2015, closing up by 1.50% [1] - The market saw over 4,100 stocks in the green, with significant contributions from financial sectors such as brokerage, insurance, and internet finance [1] Seasonal Trends - According to Zheshang Securities, the first quarter typically sees a "spring rally," where small and mid-cap growth indices perform best, setting the stage for February's market performance [1] Key Sectors Financial Sector - Major financial stocks like Dazhihui and Hualin Securities hit the daily limit, while China Ping An reached a new five-year high [1] Brain-Computer Interface - The brain-computer interface sector saw a surge, with nearly 20 stocks hitting the daily limit, driven by breakthroughs in clinical trials for a new fully implanted device [3] - The industry is expected to enter a critical phase of large-scale application, supported by policy backing and ongoing technological advancements [3] Non-Ferrous Metals - The non-ferrous metals sector strengthened, with companies like Luoyang Molybdenum and Zijin Mining reaching historical highs, influenced by rising global metal prices [4] - The London Metal Exchange reported significant price increases for tin and copper, indicating strong demand and supply dynamics [4] Solid-State Batteries - The solid-state battery sector experienced a rally, with several stocks hitting the daily limit, following the announcement of a commercially viable solid-state battery by Donut Lab [5] - The sector is expected to progress towards industrialization, supported by policy focus and active participation from industry players [5] Semiconductor Sector - The semiconductor sector remained active, with storage chips and semiconductor equipment leading the gains, as companies like Beifang Huachuang reached historical highs [6] - Price increases for DRAM chips were reported, with significant hikes expected in Q1 2026 [7] Institutional Insights - Guotai Junan Securities highlighted the internal trend of a "transformation bull market" in China, driven by economic shifts and capital market reforms [8] - Debon Securities expressed optimism for a slow bull market following the New Year, with expectations for continued upward movement in the A-share market [8] - Dongfang Securities noted that the market's upward trend is supported by strong investor confidence and the commercialization of new industries like brain-computer interfaces and AI [9]

Group 1 - The core focus of the news is the explosive growth of the brain-computer interface (BCI) sector in the A-share market, with significant stock price increases observed on the first trading day of 2026, particularly for companies involved in BCI technology [1][5] - Notable stock performances include BeiYikang with a 30% increase, and other companies like Sanbo Brain Science, Xiangyu Medical, and Meihai Medical all achieving around 20% gains [1][5] - The surge in the BCI sector is attributed to three major developments: Neuralink's announcement of large-scale production of BCI devices, the implementation of new industry standards in China, and successful clinical trials demonstrating the technology's effectiveness [3][4][6] Group 2 - Neuralink, led by Elon Musk, announced that its BCI devices will enter mass production in 2026, along with a breakthrough in automated surgical technology for implanting devices [3] - A new industry standard for BCI medical devices in China, effective January 1, 2026, aims to provide regulatory clarity and facilitate clinical trials and product approvals [4] - A successful human trial in China demonstrated the ability to restore movement in paralyzed patients using implanted electrodes, showcasing rapid advancements in BCI technology [6] Group 3 - Investment interest in the BCI sector is heightened, with major international banks like Goldman Sachs, BNP Paribas, and Morgan Stanley focusing on companies like Innovation Medical, which has a strategic advantage due to its hospital resources [8] - The global BCI market is projected to reach $12.4 billion by 2034, with a compound annual growth rate of 17% from 2025 to 2034, indicating strong long-term growth potential [9] - The potential applications of BCI technology are expanding beyond medical uses, with possibilities in consumer electronics and smart home integration, suggesting a broader market impact [11] Group 4 - Despite the excitement, challenges remain in ensuring the long-term viability of implanted electrodes and improving the accuracy of non-invasive BCI systems [12] - Following the stock price surge, regulatory bodies have issued inquiries to several companies in the BCI sector to ensure transparency regarding their business operations and R&D progress [12] - Innovation Medical's stock has seen significant increases, but analysts caution that its current valuation is high, and investors should monitor the actual progress of its BCI projects and their impact on profitability [14]

创新医疗、倍益康、三博脑科、南京熊猫、美好医疗涨停，熵基科技涨超15%，麦澜德、爱朋医疗涨超 10%。 (本文来自第一财经) ...